» Articles » PMID: 35284766

Computational Investigation of Structural Basis for Enhanced Binding of Isoflavone Analogues with Mitochondrial Aldehyde Dehydrogenase

Overview
Journal ACS Omega
Specialty Chemistry
Date 2022 Mar 14
PMID 35284766
Authors
Affiliations
Soon will be listed here.
Abstract

Isoflavone compounds are potent inhibitors against mitochondrial aldehyde dehydrogenase (ALDH2) for the treatment of alcoholism and drug addiction, and an in-depth understanding of the underlying structural basis helps design new inhibitors for enhanced binding. Here, we investigated the binding poses and strengths of eight isoflavone analogues (including CVT-10216 and daidzin) with ALDH2 via computational methods of molecular docking, molecular dynamics (MD) simulation, molecular mechanics Poisson-Boltzmann surface area (MM-PBSA), steered MD, and umbrella sampling. Neither the Vina scoring of docked and MD-sampled complexes nor the nonbonded protein-inhibitor interaction energy from MD simulations is able to reproduce the relative binding strength of the inhibitors compared to experimental IC values. Considering the solvation contribution, MM-PBSA and relatively expensive umbrella sampling yield good performance for the relative binding (free) energies. The isoflavone skeleton prefers to form π-π stacking, π-sulfur, and π-alkyl interactions with planar (Phe and Trp) or sulfur-containing (Cys and Met) residues. The enhanced inhibition of CVT-10216 originates from both end groups of the isoflavone skeleton offering strong van der Waals contacts and from the methylsulfonamide group at the 4' position by hydrogen bonding (HB) with neighboring receptor residues. These results indicate that the hydrophobic binding tunnel of ALDH2 is larger than the isoflavone skeleton in length and thus an extended hydrophobic core is likely a premise for potent inhibitors.

Citing Articles

Advances in Factors Affecting ALDH2 Activity and its Mechanisms.

Liu Y, Liu X, Pan C Cardiovasc Toxicol. 2024; 24(12):1428-1438.

PMID: 39365551 DOI: 10.1007/s12012-024-09923-9.


Repurposing Drugs for Inhibition against ALDH2 via a 2D/3D Ligand-Based Similarity Search and Molecular Simulation.

Jiang W, Chen J, Zhang P, Zheng N, Ma L, Zhang Y Molecules. 2023; 28(21).

PMID: 37959744 PMC: 10650273. DOI: 10.3390/molecules28217325.


Repurposing of World-Approved Drugs for Potential Inhibition against Human Carbonic Anhydrase I: A Computational Study.

Zheng N, Jiang W, Zhang P, Ma L, Chen J, Zhang H Int J Mol Sci. 2023; 24(16).

PMID: 37628799 PMC: 10454238. DOI: 10.3390/ijms241612619.


Structure-Based Virtual Screening of Furan-1,3,4-Oxadiazole Tethered -phenylacetamide Derivatives as Novel Class of hTYR and hTYRP1 Inhibitors.

Irfan A, Faisal S, Ahmad S, Al-Hussain S, Javed S, Zahoor A Pharmaceuticals (Basel). 2023; 16(3).

PMID: 36986444 PMC: 10059052. DOI: 10.3390/ph16030344.


Protective effects of isoflavones on alcoholic liver diseases: Computational approaches to investigate the inhibition of ALDH2 with isoflavone analogues.

Lee W, Kim S Front Mol Biosci. 2023; 10:1147301.

PMID: 36923641 PMC: 10009234. DOI: 10.3389/fmolb.2023.1147301.


References
1.
Larson H, Zhou J, Chen Z, Stamler J, Weiner H, Hurley T . Structural and functional consequences of coenzyme binding to the inactive asian variant of mitochondrial aldehyde dehydrogenase: roles of residues 475 and 487. J Biol Chem. 2007; 282(17):12940-50. PMC: 1885376. DOI: 10.1074/jbc.M607959200. View

2.
de Melo R, Lopes R, Alves J . A case of psychosis in disulfiram treatment for alcoholism. Case Rep Psychiatry. 2014; 2014:561092. PMC: 4003787. DOI: 10.1155/2014/561092. View

3.
Genheden S, Ryde U . The MM/PBSA and MM/GBSA methods to estimate ligand-binding affinities. Expert Opin Drug Discov. 2015; 10(5):449-61. PMC: 4487606. DOI: 10.1517/17460441.2015.1032936. View

4.
Klyosov A . Kinetics and specificity of human liver aldehyde dehydrogenases toward aliphatic, aromatic, and fused polycyclic aldehydes. Biochemistry. 1996; 35(14):4457-67. DOI: 10.1021/bi9521102. View

5.
Chick J . Safety issues concerning the use of disulfiram in treating alcohol dependence. Drug Saf. 1999; 20(5):427-35. DOI: 10.2165/00002018-199920050-00003. View